ADMA Biologics, Inc. (ADMA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ADMA Revenue Growth
Revenue Breakdown (FY 2024)
ADMA's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
ADMA Revenue Analysis (2014–2025)
As of May 8, 2026, ADMA Biologics, Inc. (ADMA) generated trailing twelve-month (TTM) revenue of $509.9 million, reflecting slight decline in growth of -0.3% year-over-year. The most recent quarter (Q1 2026) recorded $114.5 million in revenue, down 17.7% sequentially.
Looking at the longer-term picture, ADMA's 5-year compound annual growth rate (CAGR) stands at +64.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $510.2 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ADMA's business is primarily driven by ADMA BioManufacturing Segment (97%), and Plasma Collection Centers Segment (3%). With over half of revenue concentrated in ADMA BioManufacturing Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including GRFS (+4.1% YoY), BIO (+1.9% YoY), and PRPH (-91.6% YoY), ADMA has underperformed the peer group in terms of revenue growth. Compare ADMA vs GRFS →
ADMA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ADMACurrent | $510M | -0.3% | +64.6% | 37.5% | |
 GRFS | $7.2B | +4.1% | +6.2% | 16.4% | |
 BIO | $2.6B | +1.9% | +0.3% | 10.5% | |
 PRPH | $7M | -91.6% | -7.3% | -570.6% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 CSL | $5.0B | -0.5% | +4.8% | 19.9% |
ADMA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $510.2M | +19.6% | $292.8M | 57.4% | $191.4M | 37.5% |
| 2024 | $426.5M | +65.2% | $219.6M | 51.5% | $139.0M | 32.6% |
| 2023 | $258.2M | +67.6% | $88.9M | 34.4% | $21.6M | 8.4% |
| 2022 | $154.1M | +90.4% | $35.3M | 22.9% | $-39,365,000 | -25.5% |
| 2021 | $80.9M | +91.7% | $1.2M | 1.4% | $-58,374,000 | -72.1% |
| 2020 | $42.2M | +43.9% | $-19,071,643 | -45.2% | $-64,914,877 | -153.8% |
| 2019 | $29.3M | +72.8% | $-10,155,155 | -34.6% | $-41,424,327 | -141.1% |
| 2018 | $17.0M | -25.4% | $-25,209,345 | -148.4% | $-60,288,944 | -354.9% |
| 2017 | $22.8M | +113.5% | $-6,403,761 | -28.1% | $-39,309,996 | -172.7% |
| 2016 | $10.7M | +48.5% | $4.3M | 40.3% | $-17,330,395 | -162.6% |
See ADMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADMA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ADMA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonADMA — Frequently Asked Questions
Quick answers to the most common questions about buying ADMA stock.
Is ADMA's revenue growth accelerating or slowing?
ADMA revenue growth slowed to -0.3%, below the 5-year CAGR of +64.6%. TTM revenue is $510M. The deceleration marks a shift from historical growth rates.
What is ADMA's long-term revenue growth rate?
ADMA Biologics, Inc.'s 5-year revenue CAGR of +64.6% reflects the variable expansion pattern. Current YoY growth of -0.3% is near this long-term average.
How is ADMA's revenue distributed by segment?
ADMA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.